Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade

International Journal of Cancer

Volumn 131, Issue 5, 2012, Pages 1187-1196

  Gilbert, Rebecca ^a   Metcalfe, Chris ^a   Fraser, William D ^b   Donovan, Jenny ^a   Hamdy, Freddie ^c   Neal, David E ^d   Lane, J Athene ^a   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

25 hydroxyvitamn D; Prostate cancer; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM; VITAMIN BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; VITAMIN D;

EID: 84863188472     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27327     Document Type: Article

References (49)

1. Schwartz GG, Hanchette CL. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 2006;17:1091-101. (Pubitemid 44290774)
2. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678S-88.
3. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005;16: 83-95. (Pubitemid 40691207)
4. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P. The role of vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 2004;92:317-25. (Pubitemid 40128252)
5. Willis MS, Wians FH. The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clin Chim Acta 2003;330:57-83. (Pubitemid 36287634)
6. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999;8:241-48. (Pubitemid 29114202)
7. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med 2004;229:277-84. (Pubitemid 38372891)
8. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dial 2005;18:276-89. (Pubitemid 41159577)
9. Polek TC, Weigel NL. Vitamin D and prostate cancer. J Androl 2002;23:9-17.
10. Gilbert R, Metcalfe C, Oliver SE, Whiteman DC, Bain C, Ness AR, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int J Cancer 2009;125:1414-23.
11. World Cancer Research Fund/American Institute for Cancer R. Food, nutrition, physical activity, and the prevention of cancer: a global perspectiveed. Washington DC: AICR, 2007.
12. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD, Sterne JAC, Metcalfe C. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 2011;22:319-40.
13. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11: 847-52.
14. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004; 108:104-08. (Pubitemid 37444451)
15. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, Weinstein SJ. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested Case-Control Study. Cancer Epidemiol Biomarkers Prev 2011;20:1850-60.
16. Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009;33:435-45.
17. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010;46:3095-101.
18. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 1994;74:104-14. (Pubitemid 24187618)
19. Rowlands MA, Holly JM, Gunnell D, Gilbert R, Donovan J, Lane JA, Marsden G, Collin SM, Hamdy F, Neal DE, Martin RM. The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control 2010;21: 1829-42.
20. Borkowf CB, Albert PS, Abnet CC. Using lowess to remove systematic trends over time in predictor variables prior to logistic regression with quantile categories. Stat Med 2003;22: 1477-93. (Pubitemid 36575597)
21. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variablesed. Wiley Series in Probability and Statistics, 2008.
22. Janssen KJM, Donders AR, Harrell FE, Jr., Vergouwe Y, Chen Q, Grobbee DE, Moons KGM. Missing covariate data in medical research: To impute is better than to ignore. J Clin Epidemiol 2010;63:721-27.
23. Wood AM, White IR, Royston P. How should variable selection be performed with multiply imputed data? Stat Med 2008;27:3227-46.
24. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on categorical variables. Stata J 2009;9:466-77.
25. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, Mucci LA, Giovannucci E. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One 2011;6:e18625.
26. Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003;88:315-22. (Pubitemid 36119904)
27. Chen L, Davey SG, Evans DM, Cox A, Lawlor DA, Donovan J, Yuan W, Day IN, Martin RM, Lane A, Rodriguez S, Davis M, et al. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 2009;18:2874-81.
28. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65. (Pubitemid 38988034)
29. Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 2007;16:2784-86. (Pubitemid 351196338)
30. Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J, Hakama M. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:302-07. (Pubitemid 46383350)
31. Ruston D, Henderson L, Gregory J, Bates CJ, Prentice A, Birch M, Swan G, Farron M. The National Diet and Nutrition Survey: adults aged 19 to 64 years. Volume 4: nutritional Status (anthropometry and blood analytes), blood pressure and physical activity. 2004. Available at http://www.statistics.gov.uk/ downloads/theme-health/NDNS-V4.pdf.
32. Harris SS. Vitamin D and African Americans. J Nutr 2006;136:1126-29.
33. Iarc Working Group Reports I. Vitamin D and Cancer. http://com.iarc.fr/ en/publications/pdfsonline/wrk/wrk5/Report- VitD.pdf 2008.
34. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. JNCI Cancer Spectrum 2006;98:451-59.
35. McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flanders WD, Koenig K, Kolonel L, Laden F, Le Marchand L, Purdue M, Snyder K, Stevens VL, et al. Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010;172:21-35.
36. Egan KM, Signorello LB, Munro HM, Hargreaves MK, Hollis BW, Blot WJ. Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes Control 2008;19:527-35.
37. Tseng M, Giri V, Bruner DW, Giovannucci E. Prevalence and correlates of vitamin D status in African American men. BMC Public Health 2009; 9:191.
38. Dimitropoulou P, Martin RM, Turner EL, Lane JA, Gilbert R, Davis M, Donovan JL, Hamdy FC, Neal DE. Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. Br J Cancer 2011;104:875-81.
39. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008;87:1087S-11091.
40. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF, Chen TC. The prostate 25-hydroxyvitamin D-1{alpha}-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004;25:967-71. (Pubitemid 38898635)
41. Millen AE, Bodnar LM. Vitamin D assessment in population-based studies: a review of the issues. Am J Clin Nutr 2008;87:1102S-11105.
42. Metcalfe C, Patel B, Evans S, Ibrahim F, Anson K, Chinegwundoh F, Corbishley C, Dorling D, Thomas B, Gillatt D, Kirby R, Muir G, et al. The risk of prostate cancer amongst South Asian men in southern England: the PROCESS cohort study. BJU Int 2008;102:1407-12.
43. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010;19:927-31.
44. Bodnar LM, Catov JM, Wisner KL, Klebanoff MA. Racial and seasonal differences in 25-hydroxyvitamin D detected in maternal sera frozen for over 40 years. Brit J Nutr 2009;101: 278-84.
45. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA, Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA: J Am Med Assoc 2005;294:66-70. (Pubitemid 41002840)
46. Weinrich S, Ellison G, Weinrich M, Ross KS, Reis-Starr C. Low sun exposure and elevated serum prostate specific antigen in African American and Caucasian men. Am J Health Stud 2002;17:148-50.
47. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159:2035-39.
48. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004;38:732-44. (Pubitemid 38757522)
49. Cancer Research UK. SunSmart. 2009. Available at http://www.sunsmart.org. uk.